PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL boosted its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 22.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 47,151 shares of the biopharmaceutical company's stock after acquiring an additional 8,505 shares during the period. Tudor Investment Corp ET AL owned about 0.06% of PTC Therapeutics worth $2,128,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in PTCT. Arizona State Retirement System lifted its stake in shares of PTC Therapeutics by 1.1% in the fourth quarter. Arizona State Retirement System now owns 20,095 shares of the biopharmaceutical company's stock worth $907,000 after buying an additional 219 shares during the last quarter. Choreo LLC raised its stake in shares of PTC Therapeutics by 2.0% during the fourth quarter. Choreo LLC now owns 11,961 shares of the biopharmaceutical company's stock worth $541,000 after buying an additional 240 shares during the last quarter. Summit Investment Advisors Inc. boosted its position in shares of PTC Therapeutics by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,968 shares of the biopharmaceutical company's stock worth $360,000 after purchasing an additional 253 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of PTC Therapeutics by 78.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 613 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 270 shares in the last quarter. Finally, Janney Montgomery Scott LLC grew its stake in PTC Therapeutics by 8.3% in the fourth quarter. Janney Montgomery Scott LLC now owns 5,965 shares of the biopharmaceutical company's stock valued at $269,000 after purchasing an additional 455 shares in the last quarter.

Analyst Ratings Changes

Several equities analysts have issued reports on PTCT shares. Scotiabank started coverage on shares of PTC Therapeutics in a research report on Friday, March 7th. They issued a "sector perform" rating and a $55.00 price target for the company. Cantor Fitzgerald increased their target price on PTC Therapeutics from $76.00 to $113.00 and gave the stock an "overweight" rating in a research note on Monday, February 3rd. StockNews.com downgraded shares of PTC Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, February 17th. Morgan Stanley reissued an "overweight" rating and issued a $70.00 price objective (up from $67.00) on shares of PTC Therapeutics in a research report on Friday, March 7th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $65.00 price target on shares of PTC Therapeutics in a report on Tuesday, April 22nd. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $63.92.

Insider Activity at PTC Therapeutics

In other news, CAO Christine Marie Utter sold 879 shares of the firm's stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $50.10, for a total value of $44,037.90. Following the completion of the transaction, the chief accounting officer now directly owns 63,442 shares of the company's stock, valued at $3,178,444.20. This trade represents a 1.37 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Allan Steven Jacobson sold 1,230 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $51.52, for a total value of $63,369.60. Following the sale, the director now directly owns 19,118 shares of the company's stock, valued at approximately $984,959.36. This trade represents a 6.04 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,305 shares of company stock valued at $1,682,755. 5.50% of the stock is owned by corporate insiders.

PTC Therapeutics Stock Down 11.0 %

NASDAQ PTCT traded down $4.46 during trading hours on Tuesday, hitting $36.19. 4,181,680 shares of the company were exchanged, compared to its average volume of 831,510. The firm has a market cap of $2.85 billion, a price-to-earnings ratio of -6.09 and a beta of 0.52. PTC Therapeutics, Inc. has a 52-week low of $28.72 and a 52-week high of $58.38. The company has a 50 day moving average of $49.80 and a two-hundred day moving average of $47.05.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $10.04 EPS for the quarter, beating analysts' consensus estimates of $0.85 by $9.19. During the same period last year, the firm posted ($1.20) EPS. The business's quarterly revenue was down 9.6% on a year-over-year basis. On average, equities research analysts predict that PTC Therapeutics, Inc. will post -4.52 EPS for the current year.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.